Susquehanna International Group
AST

Susquehanna International Group’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Susquehanna International Group’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-60,989
Closed -$63.3K – 10776
2018
Q3 		$79K Buy
60,989
+18,954
+45% +$29.4K ﹤0.01% 8691
2018
Q2 		$57K Buy
42,035
+15,040
+56% +$23K ﹤0.01% 9240
2018
Q1 		$39K Sell
26,995
-136,310
-83% -$285K ﹤0.01% 9026
2017
Q4 		$368K Buy
163,305
+91,493
+127% +$232K ﹤0.01% 7215
2017
Q3 		$244K Sell
71,812
-18,200
-20% -$61.2K ﹤0.01% 7722
2017
Q2 		$320K Buy
+90,012
New +$297K ﹤0.01% 7476
2017
Q1 		– Sell
-34,373
Closed -$134K – 10916
2016
Q4 		$158K Buy
34,373
+22,187
+182% +$91.5K ﹤0.01% 8820
2016
Q3 		$52K Buy
+12,186
New +$39.4K ﹤0.01% 8115
2015
Q4 		– Sell
-23,524
Closed -$91K – 10643
2015
Q3 		$91K Buy
23,524
+7,431
+46% +$34.1K ﹤0.01% 9185
2015
Q2 		$74K Sell
16,093
-16,657
-51% -$160K ﹤0.01% 9772
2015
Q1 		$221K Buy
+32,750
New +$162K ﹤0.01% 8493

Susquehanna International Group's AST Position: Q4 2018 in Review

Susquehanna International Group sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q4 2018, closing a stake of 60,989 shares — an estimated $63.3K sold.

Susquehanna International Group first reported a position in AST in Q1 2015 and held it in 11 quarters. The position peaked at $368K in Q4 2017. 46 funds tracked by Wall St. Rank hold AST as of Q4 2018.

  • Susquehanna International Group reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q4 2018 after selling out during the quarter.
  • Susquehanna International Group sold 60,989 Asterias Biotherapeutics Inc. Series A shares in Q4 2018, an estimated $63.3K.
  • Susquehanna International Group first reported a position in Asterias Biotherapeutics Inc. Series A in Q1 2015 and held it in 11 quarters.
  • Susquehanna International Group's Asterias Biotherapeutics Inc. Series A position peaked at $368K in Q4 2017.
  • 46 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q4 2018.

Based on Susquehanna International Group's 13F filing for Q4 2018, filed 14 Feb 2019.